FX007
FX007 is a selective small-molecule TrkA antagonist that is under development by Flexion Therapeutics for the local treatment of postoperative pain. It is currently in the preclinical stage of development. The drug was licensed by Flexion from AstraZeneca. FX007 has also attracted interest as a potential treatment of osteoarthritis.[1]
See also
References
- ↑ Kavanaugh, Taylor E.; Werfel, Thomas A.; Cho, Hongsik; Hasty, Karen A.; Duvall, Craig L. (2015). "Particle-based technologies for osteoarthritis detection and therapy". Drug Delivery and Translational Research. doi:10.1007/s13346-015-0234-2. ISSN 2190-393X.
External links
| Opioids | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paracetamol-type |
| ||||||||||||||||||||||||||||||
| NSAIDs |
| ||||||||||||||||||||||||||||||
| Cannabinoids | |||||||||||||||||||||||||||||||
| Ion channel modulators |
| ||||||||||||||||||||||||||||||
| Myorelaxants | |||||||||||||||||||||||||||||||
| Others | |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the 5/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.